The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Colorectal Cancer Case Studies

Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

Tanios Bekaii-Saab, MD
Published Online:Apr 26, 2016
Case 2 examines a 52-year-old woman newly diagnosed with metastatic CRC who is genotyped as part of her initial work up.

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2


What is the clinical importance of RAS mutations in treatment of metastatic CRC?

The presence or a RAS mutation essentially tells you that this patient should not receive an EGFR inhibitor. There's not just a clear lack of benefit, but if you actually dissect out the data from the data that looked at these agents, patients who receive EGFR inhibitors that do have all RAS mutation end up doing worse than those on chemotherapy alone. This may induce the harm of toxicity and the harm of losing benefit if a patient has those mutations and you administer the EGFR inhibitor.

Unresectable Colon Cancer: Case 2

52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.

Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.